- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05046106
MLC1501 Study Assessing Efficacy in STROke Recovery (MAEStro)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Efficacy and Safety Study of MLC1501 in Patients With Stroke
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 540 patients will be included with approximately 180 participants randomized to each treatment arm. Randomization will be performed centrally and stratified according to the following factors at the time of randomization: NIHSS (8 to 12, 13 to 18), age (<65 years, ≥65 years) and received either intravenous or endovascular thrombolysis/thrombectomy (no, yes).
Efficacy clinical assessments will include mRS, FMA, ARAT, 10MWT, NIHSS, Barthel Index, EQ-5D-5L, MoCA, PROMIS-10, and occurrence of recurrent vascular event.
Each participant will undergo standard safety assessments including physical exam and laboratory parameters, and be observed for adverse events for the duration of the study. Electrocardiogram (ECG), hematology, clinical chemistry, coagulation, and urinalysis will be performed at specified intervals. The C-SSRS will be used to screen for suicidal ideation and behavior. Blood samples will be collected and stored for future studies on circulating compounds and pharmacokinetics.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Emily Lim
- Phone Number: 184 +65 62113710
- Email: emily.lim@moleac.com
Study Contact Backup
- Name: Robert N Gan, MD
- Phone Number: +65 62113710
- Email: robert.gan@moleac.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female.
- 18 years old or older.
- Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 7 days prior to inclusion. Patients who undergo intravenous or endovascular thrombolysis or thrombectomy must be considered stable for at least 24 hours post-procedure prior to inclusion.
- NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 2 on the NIHSS motor items 5A or 5B and/or 6A or 6B.
- A candidate for active rehabilitation in the opinion of the treating physician.
- Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed.
Exclusion Criteria:
- Pre-stroke modified Rankin score of >1.
- Contraindication to any of the study procedures.
- Participation in another investigational drug or device trial within the past 30 days.
- Intake of warfarin in the past one week or expected to be on warfarin while in the study.
- Women who are pregnant, breastfeeding, of child-bearing potential or planning to become pregnant during the study. Menopausal/post-menopausal women without menstruation for 12 consecutive months or surgically sterilized women may be included. Intake of oral contraceptive pills or hormone replacement therapy is not allowed. Use of mechanical barriers, e.g., condom, intrauterine device, are allowed. Local contraception requirements for clinical trials should be followed.
- Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae/Leguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae/Umbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark).
- Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability.
- Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis.
- Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his/her participation in this study, may hamper his/her ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
500-mg placebo capsule, 4 capsules twice a day for 24 weeks.
|
Caramel, chocolate brown, flavor (E_1982648), dextrin
|
Active Comparator: MLC1501 Low-dose
MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
|
Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
|
Active Comparator: MLC1501 High-dose
MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
|
Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
modified Rankin Scale
Time Frame: 24 weeks
|
The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 (no symptoms at all) to 5 (severe disability).
A separate category of 6 is usually added for patients who expire.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fugl-Meyer motor Assessment (FMA)
Time Frame: 12, 24 weeks
|
12, 24 weeks
|
|
Action Research Arm Test (ARAT)
Time Frame: 12, 24 weeks
|
12, 24 weeks
|
|
Timed 10-Meter Walk Test (10MWT)
Time Frame: 12, 24 weeks
|
12, 24 weeks
|
|
National Institute of Health Stroke Scale total and motor scores
Time Frame: 12, 24 weeks
|
The maximum possible score is 42 (severe), with the minimum score being a 0 (no symptoms)
|
12, 24 weeks
|
Barthel Index
Time Frame: 4, 12, 24, 36 weeks
|
4, 12, 24, 36 weeks
|
|
EuroQol 5 Dimensions 5 Levels
Time Frame: 4, 12, 24, 36 weeks
|
EQ5D-5L has 5 response levels: level 1 (no problems), 2 (slight), 3 (moderate), 4 (severe).
Sometimes it is more convenient to dichotomies the levels into 'no problem's (level 1) and 'any problems' (level 2 to 5).
In total, there are 3,125 possible unique health states defined by the EQ-5D-5L, with 11111 and 55555 representing the best and worst health states
|
4, 12, 24, 36 weeks
|
Montreal Cognitive Assessment (MoCA)
Time Frame: 12, 24 weeks
|
12, 24 weeks
|
|
Occurrence of recurrent vascular event
Time Frame: 24, 36 weeks
|
24, 36 weeks
|
|
Patient Reported Outcome Measurement Information System - Global Health
Time Frame: 12, 24 weeks
|
The PROMIS Global-10 is a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales.
The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score.
These scores are then standardized to the general population, using the "T-Score".
The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points.
Higher scores indicate a healthier patient.
|
12, 24 weeks
|
Columbia-Suicide Severity Rating Scale screen
Time Frame: 4, 12, 24, 36 weeks
|
There are no specified clinical cutoffs for the C-SSRS due to the binary nature of the responses to items. When an item is endorsed, the clinician must pose follow-up inquiries to obtain additional information. The following can inform safety monitoring and treatment planning when patients endorse suicidal ideation, suicidal behavior, or both:
|
4, 12, 24, 36 weeks
|
Adverse events
Time Frame: up to 36 weeks
|
Listing and calculating the number and percentage of subjects experiencing non-serious and serious adverse events for each dose cohort
|
up to 36 weeks
|
modified Rankin Scale
Time Frame: 4, 12 and 36 weeks
|
The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 (no symptoms at all) to 5 (severe disability).
A separate category of 6 is usually added for patients who expire.
|
4, 12 and 36 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christopher Chen, BMBCh, MRCP, FAMS, FRCPE, Departments of Pharmacology and Psychological Medicine, National University of Singapore
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Infarction
- Myocardial Infarction
- Stroke
- Ischemic Stroke
- Embolic Stroke
- Thrombotic Stroke
Other Study ID Numbers
- EFSA2019_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
University Hospital Inselspital, BerneUnknownEmergencies | Stroke, Acute | Stroke Hemorrhagic | Diagnostic Self Evaluation | Strokes Thrombotic | Stroke SyndromeSwitzerland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States